(Q34974991)

5 August 2017

1 reference

title

PET for in vivo pharmacokinetic and pharmacodynamic measurements (English)

1 reference

ORCID Public Data File 2021

5 August 2017

1 reference

author name string

Gupta N

series ordinal

1

1 reference

PubMed ID

12387835

5 August 2017

Price PM

series ordinal

2

1 reference

PubMed ID

12387835

5 August 2017

Aboagye EO

series ordinal

3

1 reference

5 August 2017

1 November 2002

1 reference

European Journal of Cancer

5 August 2017

1 reference

5 August 2017

38

1 reference

5 August 2017

2094-2107

1 reference

5 August 2017

16

1 reference

Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Breast cancer: PET imaging of estrogen receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Asymmetric synthesis of a precursor for the automated radiosynthesis of S-(3'-t-butylamino-2'-hydroxypropoxy)-benzimidazol-2-[11C]one (S-[11C]CGP 12177) as a preferred radioligand for beta-adrenergic receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Spectral analysis of dynamic PET studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Temozolomide in patients with high grade gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

A phase II study of temozolomide in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

A phase II study of temozolomide in advanced untreated pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Phase II study of Temodal in the treatment of patients with advanced nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Selectivity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide towards Lewis lung carcinoma and human tumour cell lines in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Carbon-11 labelling of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and determination of plasma metabolites in man

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Automated radiosyntheses of [6-O-methyl-11C]diprenorphine and [6-O-methyl-11C]buprenorphine from 3-O-trityl protected precursors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II. CRC Phase I/II Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Pharmacokinetics and toxicity of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Fluorouracil: biochemistry and pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Perfusion of colorectal liver metastases and uptake of fluorouracil assessed by H2(15)O and [18F]uracil positron emission tomography (PET)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Intra- and extracellular fluorouracil uptake: assessment with contrast-enhanced metabolic F-19 MR imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Human tumor fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Association of intratumoral pharmacokinetics of fluorouracil with clinical response

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Imaging proliferation in vivo with [F-18]FLT and positron emission tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

The synthesis of 7 alpha-methyl-substituted estrogens labeled with fluorine-18: potential breast tumor imaging agents

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Synthesis of [18F]fluoro-labeled progestins for PET

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

1 reference

7 January 2021

Fluorine-18-labeled progestin 16 alpha, 17 alpha-dioxolanes: development of high-affinity ligands for the progesterone receptor with high in vivo target site selectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

The clinical relevance of multidrug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Biochemistry of multidrug resistance mediated by the multidrug transporter

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

P-glycoproteins: mediators of multidrug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Visualization of multidrug resistance in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Radiolabelled tracers and anticancer drugs for assessment of therapeutic efficacy using PET.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Clinical implications of circulating angiogenic factors in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Redefining the target: chemotherapeutics as antiangiogenics

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

In vivo detection and imaging of phosphatidylserine expression during programmed cell death

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Will imaging of apoptosis play a role in clinical care? A tale of mice and men.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

In vivo and in vitro measurement of apoptosis in breast cancer cells using 99mTc-EC-annexin V.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

A modeling approach for quantifying tumor hypoxia with [F-18]fluoromisonidazole PET time-activity data.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Antibody-directed enzyme prodrug therapy (ADEPT) for treatment of major solid tumour disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Molecular imaging: exploring the next frontier

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

New approaches for imaging in gene therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

In vivo monitoring of drugs using radiotracer techniques

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900413-6

7 January 2021

10.1016/S0959-8049(02)00413-6

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12387835